Bruker Corporation $BRKR Shares Purchased by Aquatic Capital Management LLC

Aquatic Capital Management LLC raised its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 120.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 349,596 shares of the medical research company’s stock after buying an additional 190,883 shares during the period. Aquatic Capital Management LLC owned about 0.23% of Bruker worth $11,358,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BRKR. Sector Gamma AS lifted its holdings in shares of Bruker by 28.0% during the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock valued at $8,152,000 after acquiring an additional 54,939 shares in the last quarter. Becker Capital Management Inc. increased its holdings in Bruker by 606.8% in the 3rd quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after purchasing an additional 258,545 shares in the last quarter. DNB Asset Management AS raised its position in Bruker by 40.5% in the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the period. M&G PLC raised its position in Bruker by 233.0% in the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after purchasing an additional 766,992 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in shares of Bruker by 52.5% during the third quarter. New York State Common Retirement Fund now owns 370,797 shares of the medical research company’s stock worth $12,047,000 after purchasing an additional 127,698 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BRKR shares. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. Rothschild & Co Redburn set a $60.00 target price on Bruker in a report on Thursday, November 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. JPMorgan Chase & Co. increased their price objective on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Barclays dropped their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus price target of $50.38.

Bruker Stock Down 3.7%

Shares of NASDAQ BRKR opened at $33.75 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22. The stock’s 50-day simple moving average is $43.50 and its 200-day simple moving average is $41.11. The firm has a market cap of $5.14 billion, a price-to-earnings ratio of -225.00, a PEG ratio of 2.02 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. During the same period in the prior year, the company posted $0.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio (DPR) is presently -133.33%.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.30% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.